Pharma giants back a leader in virtual clinical trials as Covid-19 blights sites
While traditional trial sites are under enormous pressure amid the Covid-19 pandemic, 3 pharma giants continue to back a leader in virtual clinical trials.
Los Angeles-based Science 37 closed a $40 million funding round on Friday, with investments from Novartis, Amgen and Sanofi Ventures. Lux Capital, Redmile Group and PPD led the round, and LifeSci Ventures and Mubadala Ventures joined in for the first time.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters